公开(公告)号：USD686628S1

公开(公告)日：2013-07-23

申请号：US29419798

申请日：2012-05-02

申请人： John A. Hall

设计人： John A. Hall

公开(公告)号：US20100318371A1

公开(公告)日：2010-12-16

申请号：US12483071

申请日：2009-06-11

申请人： Johnny R. Sanders, JR. ,  Denise A. Tuck ,  Patrick J. Finley ,  Cliff Paterson ,  John A. Hall

发明人： Johnny R. Sanders, JR. ,  Denise A. Tuck ,  Patrick J. Finley ,  Cliff Paterson ,  John A. Hall

IPC分类号： G06Q99/00 ,  G06F17/30 ,  G06F17/00

CPC分类号： G06Q30/0282 ,  G16H50/30 ,  G16H50/80

摘要： A comprehensive hazard evaluation system and method for chemicals and products. The system includes a memory and a processor. The memory stores the component make-up for each of a number of products. The memory also stores an environmental hazard score, an environmental health hazard score, and a physical hazard score for each component. A product hazard score is determined and stored based on the environmental hazard score, the environmental health hazard score, and the physical hazard score. The processor is operable to process user request and to display the product hazard score for at least one product on a display.

摘要翻译： 化学品和产品的综合危害评估系统和方法。 该系统包括一个存储器和一个处理器。 内存存储各种产品的组件组成。 记忆还存储每个组分的环境危害分数，环境健康危害分数和物理危害分数。 根据环境危害分数，环境健康危害分数和身体危害分数确定并存储产品危害分数。 处理器可操作以处理用户请求并且在显示器上显示至少一种产品的产品危害分数。

公开(公告)号：US07195886B2

公开(公告)日：2007-03-27

申请号：US10733816

申请日：2003-12-10

申请人： Stephen D Harrison ,  John A Hall ,  Maria Calderon-Cacia ,  Ziyang Zhong ,  Eric Y Fang ,  Doris G Coit ,  Steve H Nguyen ,  Angelica Medina-Selby

发明人： Stephen D Harrison ,  John A Hall ,  Maria Calderon-Cacia ,  Ziyang Zhong ,  Eric Y Fang ,  Doris G Coit ,  Steve H Nguyen ,  Angelica Medina-Selby

IPC分类号： C12Q1/48 ,  G01N33/53 ,  G01N33/00 ,  G01N33/563 ,  C12P21/06 ,  C12P21/08 ,  C12N9/12 ,  C12N5/02 ,  C12N5/06 ,  C12N15/00 ,  C07K14/00

CPC分类号： C12N9/1205 ,  C12Q1/485 ,  C12Y207/01037 ,  G01N2500/00

摘要： The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.

公开(公告)号：US07135321B2

公开(公告)日：2006-11-14

申请号：US10689461

申请日：2003-10-20

申请人： Stephen D Harrison ,  John A Hall ,  Maria Calderon-Cacia ,  Ziyang Zhong ,  Eric Y Fang ,  Doris G Coit ,  Steve H Nguyen ,  Angelica Medina-Selby

发明人： Stephen D Harrison ,  John A Hall ,  Maria Calderon-Cacia ,  Ziyang Zhong ,  Eric Y Fang ,  Doris G Coit ,  Steve H Nguyen ,  Angelica Medina-Selby

IPC分类号： C12N9/12 ,  C12Q1/48 ,  C12P21/06 ,  C12N15/54 ,  C12N15/70 ,  C12N5/00 ,  C12N1/00 ,  C07H21/04

CPC分类号： C12N9/1205 ,  C12Q1/485 ,  C12Y207/01037 ,  G01N2500/00

摘要： The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.

公开(公告)号：US06274148B1

公开(公告)日：2001-08-14

申请号：US08249843

申请日：1994-05-26

申请人： Robert O. Ralston ,  Frank Marcus ,  Kent B. Thudium ,  Barbara A. Gervase ,  John A. Hall ,  Kim M. Berger ,  Qui-Lim Choo ,  Michael Houghton ,  George Kuo

发明人： Robert O. Ralston ,  Frank Marcus ,  Kent B. Thudium ,  Barbara A. Gervase ,  John A. Hall ,  Kim M. Berger ,  Qui-Lim Choo ,  Michael Houghton ,  George Kuo

IPC分类号： A61K3929

CPC分类号： C07K14/005 ,  A61K39/00 ,  C12N2770/24222 ,  Y10S530/82 ,  Y10S530/826 ,  Y10S977/802 ,  Y10S977/803 ,  Y10S977/804 ,  Y10S977/915 ,  Y10S977/918

摘要： Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.

摘要翻译： 两种丙型肝炎病毒包膜蛋白（E1和E2）不表达唾液酸化。 这些蛋白质在低等真核生物或其末端糖基化被阻断的哺乳动物细胞中的重组表达导致与天然HCV糖蛋白更相似的重组蛋白质。 当通过GNA凝集素亲和力分离时，E1和E2蛋白聚集成病毒样颗粒。

公开(公告)号：US6074852A

公开(公告)日：2000-06-13

申请号：US443900

申请日：1995-05-17

申请人： Robert O. Ralston ,  Frank Marcus ,  Kent B. Thudium ,  Barbara A. Gervase ,  John A. Hall ,  Kim M. Berger ,  Qui-Lim Choo ,  Michael Houghton ,  George Kuo

发明人： Robert O. Ralston ,  Frank Marcus ,  Kent B. Thudium ,  Barbara A. Gervase ,  John A. Hall ,  Kim M. Berger ,  Qui-Lim Choo ,  Michael Houghton ,  George Kuo

IPC分类号： G01N33/576 ,  A61K35/16 ,  A61K38/00 ,  A61K38/10 ,  A61K39/00 ,  A61K39/29 ,  A61P1/16 ,  A61P31/12 ,  C07K14/18 ,  C12N1/19 ,  C12N5/10 ,  C12N15/09 ,  C12N15/51 ,  C12P21/02 ,  C12P21/04 ,  C12Q1/70

CPC分类号： C07K14/005 ,  A61K39/00 ,  C12N2770/24222 ,  Y10S530/82 ,  Y10S530/826 ,  Y10S977/802 ,  Y10S977/803 ,  Y10S977/804 ,  Y10S977/915 ,  Y10S977/918

摘要： Two Hepatitis C Virus envelope proteins (E1 and E2) are expressed without sialylation. Recombinant expression of these proteins in lower eukaryotes, or in mammalian cells in which terminal glycosylation is blocked, results in recombinant proteins which are more similar to native HCV glycoproteins. When isolated by GNA lectin affinity, the E1 and E2 proteins aggregate into virus-like particles.

公开(公告)号：US07807430B2

公开(公告)日：2010-10-05

申请号：US12074543

申请日：2008-03-03

申请人： Stephen D Harrison ,  John A Hall ,  Maria Calderon-Cacia ,  Ziyang Zhong ,  Eric Y Fang ,  Doris G Coit ,  Steve H Nguyen ,  Angelica Medina-Selby

发明人： Stephen D Harrison ,  John A Hall ,  Maria Calderon-Cacia ,  Ziyang Zhong ,  Eric Y Fang ,  Doris G Coit ,  Steve H Nguyen ,  Angelica Medina-Selby

IPC分类号： C12N9/12 ,  C07K14/00 ,  C12P21/00 ,  C12N1/21 ,  C12N15/00 ,  C12N5/10 ,  C12Q1/48 ,  C07H21/00

CPC分类号： C12N9/1205 ,  C12Q1/485 ,  C12Y207/01037 ,  G01N2500/00

摘要： The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3α and GSK3β polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.

摘要翻译： 本发明提供能够结晶的截短的GSK3多肽，包括GSK3α和GSK3＆bgr; 多肽，以及使用这些多肽来鉴定和优化GSK3抑制剂。 还提供了具有与野生型GSK3不同的至少一个取代的氨基酸的GSK3多肽，其中取代的氨基酸不能被磷酸化。 本发明用于提供鉴定和优化用于治疗由GSK3活性介导的疾病（包括阿尔茨海默病，2型糖尿病和炎症）的化合物的方法。

公开(公告)号：US06716624B2

公开(公告)日：2004-04-06

申请号：US10211412

申请日：2002-07-31

申请人： Stephen D. Harrison ,  John A. Hall ,  Maria Calderon-Cacia ,  Ziyang Zhong ,  Eric Y. Fang ,  Doris G. Coit ,  Steve H. Nguyen ,  Angelica Medina-Selby

发明人： Stephen D. Harrison ,  John A. Hall ,  Maria Calderon-Cacia ,  Ziyang Zhong ,  Eric Y. Fang ,  Doris G. Coit ,  Steve H. Nguyen ,  Angelica Medina-Selby

IPC分类号： C12N912

CPC分类号： C12N9/1205 ,  C12Q1/485 ,  C12Y207/01037 ,  G01N2500/00

摘要： The invention provides truncated GSK3 polypeptides capable of crystallization, including GSK3&agr; and GSK3&bgr; polypeptides, and use of these polypeptides to identify and optimize GSK3 inhibitors. Also provided are GSK3 polypeptides having at least one substituted amino acid that differs from wild-type GSK3, wherein the substituted amino acid is incapable of being phosphorylated. The invention finds use in providing methods of identifying and optimizing compounds useful for treating diseases mediated by GSK3 activity, including Alzheimer's disease, type 2 diabetes, and inflammation.

摘要翻译： 本发明提供能够结晶的截短的GSK3多肽，包括GSK3α和GSK3β多肽，以及使用这些多肽来鉴定和优化GSK3抑制剂。 还提供了具有与野生型GSK3不同的至少一个取代的氨基酸的GSK3多肽，其中取代的氨基酸不能被磷酸化。 本发明用于提供鉴定和优化用于治疗由GSK3活性介导的疾病（包括阿尔茨海默病，2型糖尿病和炎症）的化合物的方法。

公开(公告)号：US2481709A

公开(公告)日：1949-09-13

申请号：US74384547

申请日：1947-04-25

申请人： T A HARDIN ,  JOHN A HALL ,  GROVER C PAGE ,  JAS A PARKER

发明人： ADAMS WILLIAM C

IPC分类号： A63B71/06

CPC分类号： A63B71/0672 ,  Y10S273/26

公开(公告)号：US864138A

公开(公告)日：1907-08-20

申请号：US1906322505

申请日：1906-06-20

申请人： JOHN A HALL ,  PHELPS SIDNEY W

发明人： PHELPS SIDNEY W

CPC分类号： A41F15/02 ,  Y10T24/44538 ,  Y10T24/44564